Overview

Study to Access the Relative Bioavailability of Subcutaneous Dose of Nemolizumab When Administered Via Auto-Injector Versus Dual-Chamber Syringe

Status:
Not yet recruiting
Trial end date:
2023-01-31
Target enrollment:
Participant gender:
Summary
This study is to compare the rate and extent of absorption of a single dose of nemolizumab administered with auto-injectors [AI] (test) versus dual-chamber syringes [DCS] (reference) under controlled conditions in healthy adult subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Galderma R&D